These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35871310)

  • 1. SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies.
    Terpos E; Fotiou D; Karalis V; Ntanasis-Stathopoulos I; Sklirou AD; Gavriatopoulou M; Malandrakis P; Iconomidou VA; Kastritis E; Trougakos IP; Dimopoulos MA
    Am J Hematol; 2022 Oct; 97(10):1300-1308. PubMed ID: 35871310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
    Gavriatopoulou M; Terpos E; Kastritis E; Briasoulis A; Gumeni S; Ntanasis-Stathopoulos I; Sklirou AD; Malandrakis P; Eleutherakis-Papaiakovou E; Migkou M; Trougakos IP; Dimopoulos MA
    Clin Exp Med; 2022 May; 22(2):319-323. PubMed ID: 34283338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    Qin K; Honjo K; Sherrill-Mix S; Liu W; Stoltz RM; Oman AK; Hall LA; Li R; Sterrett S; Frederick ER; Lancaster JR; Narkhede M; Mehta A; Ogunsile FJ; Patel RB; Ketas TJ; Cruz Portillo VM; Cupo A; Larimer BM; Bansal A; Goepfert PA; Hahn BH; Davis RS
    PLoS Med; 2023 Jun; 20(6):e1004157. PubMed ID: 37384638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor neutralizing antibody responses in 106 patients with WM after vaccination against SARS-CoV-2: a prospective study.
    Gavriatopoulou M; Terpos E; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Kastritis E; Trougakos IP; Dimopoulos MA
    Blood Adv; 2021 Nov; 5(21):4398-4405. PubMed ID: 34529762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Lymphocyte Phenotypic Alterations on the Humoral Response to Vaccination Against SARS-COV-2 in Dialysis Patients.
    Lioulios G; Fylaktou A; Asouchidou D; Xochelli A; Nikolaidou V; Stai S; Christodoulou M; Giamalis P; Tsouchnikas I; Papagianni A; Stangou M
    Ann Lab Med; 2023 Sep; 43(5):451-460. PubMed ID: 37080746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor Neutralizing Antibody Responses in 132 Patients with CLL, NHL and HL after Vaccination against SARS-CoV-2: A Prospective Study.
    Terpos E; Gavriatopoulou M; Fotiou D; Giatra C; Asimakopoulos I; Dimou M; Sklirou AD; Ntanasis-Stathopoulos I; Darmani I; Briasoulis A; Kastritis E; Angelopoulou M; Baltadakis I; Panayiotidis P; Trougakos IP; Vassilakopoulos TP; Pagoni M; Dimopoulos MA
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
    Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
    BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222.
    Terpos E; Karalis V; Ntanasis-Stathopoulos I; Evangelakou Z; Gavriatopoulou M; Manola MS; Malandrakis P; Gianniou DD; Kastritis E; Trougakos IP; Dimopoulos MA
    Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma.
    Nooka AK; Shanmugasundaram U; Cheedarla N; Verkerke H; Edara VV; Valanparambil R; Kaufman JL; Hofmeister CC; Joseph NS; Lonial S; Azeem M; Manalo J; Switchenko JM; Chang A; Linderman SL; Roback JD; Dhodapkar KM; Ahmed R; Suthar MS; Neish AS; Dhodapkar MV
    J Clin Oncol; 2022 Sep; 40(26):3057-3064. PubMed ID: 35259002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment.
    Terpos E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Malandrakis P; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
    Blood Cancer J; 2021 Aug; 11(8):138. PubMed ID: 34341335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine - A Prospective Observational Study.
    Herzberg J; Fischer B; Becher H; Becker AK; Honarpisheh H; Guraya SY; Strate T; Knabbe C
    Front Immunol; 2022; 13():896151. PubMed ID: 35844588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.
    Gavriatopoulou M; Terpos E; Malandrakis P; Ntanasis-Stathopoulos I; Briasoulis A; Gumeni S; Fotiou D; Papanagnou ED; Migkou M; Theodorakakou F; Eleutherakis-Papaiakovou E; Kanellias N; Trougakos IP; Kastritis E; Dimopoulos MA
    Br J Haematol; 2022 Jan; 196(2):356-359. PubMed ID: 34528249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Serra F; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Oct; 7(5):100574. PubMed ID: 36029652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.